MarketBeat
21 Nov 2026, 23:12 UTC · 7h ago
Nektar Therapeutics Targets December for Phase 3 Alopecia Trial as REZPEG Advances
Impact · against what's priced in
Nektar provides a concrete clinical roadmap that expands the potential value of REZPEG into alopecia areata and clarifies the durability benchmarks for atopic dermatitis. While the atopic dermatitis top-line results are distant (mid-2028), the upcoming Q1 2027 durability data and the December Phase 3 start for alopecia create near-term catalysts.
- NKTR+0.50
No priced-in read yet





